Many small / macro molecule-based STING pathway modulators are currently being evaluated

In recent years, the concept of STING pathway targeting therapeutics has generated a lot of enthusiasm within the medical science community. The growing popularity of this therapeutic technique has not only garnered the interest of several medical researchers (reflected in the increasing volume of scientific literature (1,000+ articles published since 2015) on this subject), but also industry stakeholders focused on drug development (evident in the growing number of clinical trials and the grants awarded for STING focused projects in the recent past).

Key Inclusions

 

• A detailed assessment of the current market landscape of therapeutics targeting STING pathway, based on several parameters, such as type of STING modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, biologics and others), phase of development (discovery, preclinical and clinical), target therapeutic area(s), type of therapy (monotherapy and combination therapy), route of administration (intratumoral, intravenous and others), and line of treatment (last line, second line or greater and first line or greater). The chapter also features an analysis of the developer landscape (including information on year of establishment, company size, geography and most active players). Further the chapter includes an analysis on the clinical trials focused on STING, along with information on parameters, such as recruitment status, study design and clinical endpoints.
• A detailed chapter highlighting various technology platforms that are being actively used for the development of STING modulators and analysis based on several parameters, such as type of modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, live biotherapeutics, nanoparticles and synthetic peptides), and analysis based on technology developer landscape (including information on year of establishment, company size and geography).
• Elaborate profiles of key players that are engaged in the development of therapeutics targeting STING pathway (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, recent developments and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications and current status of development.
• Tabulated profiles of industry players (shortlisted on the basis of the antagonist in pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, key members of the executive team and recent developments), along with descriptions of their respective drug candidates.
• A study on various grants that have been awarded to research institutes engaged in projects related to STING pathway, during the period 2015 - Q1 2020, based on multiple parameters, such as number of grants awarded, amount awarded, funding institute, support period, funding mechanism, type of grant application, grant activity code, most popular NIH department, type of recipient organization, regional distribution, most popular recipient organization(s), prominent project leader(s) and study section. It also includes an analysis of on grant attractiveness.

 

To order this 310+ page report, which features 170+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html

 

The USD 2.8 billion (by 2030) financial opportunity within the STING pathway targeting technologies market has been analysed across the following segments:

• Types of Payment
• Upfront Payments
• Milestone Payments

 

• Type of STING Modulator
• Agonist
• Antagonist

 

• Key Therapeutic Area(s)
• Oncological Disorders
• Inflammatory Disorders
• Infectious Diseases
• Others

 

• Route of Administration
• Intratumoral
• Intravenous
• Oral
• Subcutaneous
• Others

 

• Type of Molecule
• Non-nucleotide
• Cyclic Dinucleotide
• Live Biotherapeutics
• Oncolytic Peptides
• Synthetic Peptides
• Others

 

• Key Geographical Regions
• North America
• Europe
• Asia-Pacific

 

The STING Pathway Targeting Therapeutics and Technologies, 2020-2030. report features the following companies, which we identified to be key players in this domain:

• Aduro Biotech
• Bristol Myers Squibb
• Eisai
• GlaxoSmithKline
• ImmuneSensor Therapeutics
• Merck
• Noxopharm
• Spring Bank Pharmaceuticals
• Synlogic

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. STING Pathway Targeting Therapeutics: Current Market Landscape
 

5. STING Pathway Targeting Technologies: Current Market landscape
 

6. Company Profiles
 

7. Academic Grant Analysis
 

8. STING Related Initiatives of Big Pharmaceutical Players
 

9. Start-up Health Indexing
 

10. Publication Analysis
 

11. Partnerships and Collaborations

 

12. Funding and Investment Analysis
 

13. Market Sizing and Opportunity Analysis
 

14. Executive Insights

 

15. Concluding Remarks

 

16. Appendix 1: Tabulated Data

 

17. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]